首席执行官
Vincent J. Angotti is the Chief Executive Officer and a director of Talphera, Inc. (TLPH), positions he has held since March 2017.[[1]](https://talphera.com/team/vincent-j-angotti/)[[2]](https://fintool.com/app/research/companies/TLPH/people/vincent-angotti)[[3]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlph/talphera/management) Aged 57, he brings over two decades of experience leading executive and commercial teams in public and private life sciences companies.[[1]](https://talphera.com/team/vincent-j-angotti/)[[2]](https://fintool.com/app/research/companies/TLPH/people/vincent-angotti) Prior to Talphera (formerly AcelRx Pharmaceuticals), he served as CEO of XenoPort, Inc., where he orchestrated the acquisition of Horizant from GSK, executed a successful rebranding and relaunch, culminating in XenoPort's $0.5 billion acquisition by Arbor Pharmaceuticals in 2016.[[1]](https://talphera.com/team/vincent-j-angotti/)
Angotti holds a B.S. in Business Management from Cornell University and an MBA with honors from Columbia University.[[2]](https://fintool.com/app/research/companies/TLPH/people/vincent-angotti) He owns approximately 0.79% of Talphera's shares, valued at around $321,000, and his total compensation is about $1.04 million annually, comprising 64% salary and 36% bonuses/stock/options.[[2]](https://fintool.com/app/research/companies/TLPH/people/vincent-angotti)[[3]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlph/talphera/management) Recently, on February 12, 2026, he purchased 105,364 shares at $0.8123 each, along with 594,000 stock options, demonstrating confidence in the company amid its development-stage focus on products like Niyad for CRRT anticoagulation.[[4]](https://www.gurufocus.com/insider/29206/vincent-j.-angotti)[[5]](https://www.stocktitan.net/sec-filings/TLPH/form-4-talphera-inc-insider-trading-activity-519d79c3f983.html)[[6]](https://www.investing.com/news/insider-trading-news/talphera-tlph-ceo-angotti-buys-85k-in-shares-93CH-4517420)
查看完整内部人档案 →